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Abstract
To elucidate the function of MAS-related GPCR, member D (MRGD) in cancers, we investigated the in vitro and in vivo
oncogenic function of MRGD using murine fibroblast cell line NIH3T3 in which MRGD is stably expressed. The expression
pattern of MRGD in clinical samples was also analyzed. We found that overexpression of MRGD in NIH3T3 induced focus
formation and multi-cellular spheroid formation, and promoted tumors in nude mice. In other words, overexpression of
MRGD in NIH3T3 induced the loss of contact inhibition, anchorage-independent growth and in vivo tumorigenesis.
Furthermore, it was found that the ligand of MRGD, beta-alanine, enhanced spheroid formation in MRGD-expressing NIH3T3
cells. From investigation of clinical cancer tissues, we found high expression of MRGD in several lung cancers by
immunohistochemistry as well as real time PCR. Based on these results, MRGD could be involved in tumorigenesis and could
also be a novel anticancer drug target.
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Introduction
G protein-coupled receptor (GPCR) family members activate
various physiological signaling and play an important role in the
development as well as function of each organ [1]. In addition,
diverse GPCRs have been found to be overexpressed in primary
and metastatic tumor cells of head and neck squamous cell
carcinoma, non-small cell lung cancer, breast, prostate and gastric
tumors, melanoma and diffused large B cell lymphoma [2]. Some
GPCRs have also been reported to be functionally involved in the
cancer progression [3], such as gastrin-releasing peptide receptor
(GRPR) in prostate cancer [4], CXCR4 in metastasis [5] and so
forth. MAS1, is the first GPCR to be reported to have any relation
to cancer development. It was reported that NIH3T3 cells
ectopically expressing MAS1 promoted focus formation in vitro
and facilitated tumorigenesis in nude mice [6], however, neither
significant MAS1 expression nor active MAS1 mutation have been
reported in clinical cancers, therefore, the role of MAS1 in cancer
is still unclear. On the other hand, high expression of MAS1 was
observed in the central nervous system, such as hippocampus and
cerebellum, and MAS1 enhanced the ligand-dependent calcium
influx of Ang II receptor (AT2R) where MAS1 formed a complex
with AT2R. These suggest that MAS1 plays an important role in
the central nervous system [7,8].
MAS-related G-protein coupled receptor, D (MRGD), also
referred to as hGPCR45 [9] or TGR7 [10], was identified as a
novel GPCR in murine and human genomes [11]. It was found
that MRGD serves as the receptor of beta-alanine [12]. Several
MRG family members were reported to be expressed in specific
subpopulations of sensory neurons, which detect pain stimuli [11].
As for MRGD, its expression was found in dorsal root ganglia
(DRG) and co-localized with Vanilloid receptor-1 (VR-1), which is
an essential receptor for heat and pain sensation [12]. Moreover,
genetic ablation of MRGD expressing neuron reduces behavioral
sensitivity to noxious mechanical stimuli but not to heat or cold
stimuli in mice [13]. Thus, MRGD is considered to be one of the
players in pain sensation and/or transduction. It was also reported
that MRGD transduces intracellular signaling of the angiotensin
(Ang) II metabolite, Ang-(1–7) [14]. As described above, the
function of MRGD in the central nervous system has been
observed by several groups.
There are several GPCR family members showing amino acid
sequence similarity to MAS1 such as MRGA, MRGB, MRGC,
MRGD, MRGE, MRGF, MRGG, MRGH and MRGX [11]. In
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MRGF and MRGH are categorized as belonging to the same
branch [11]. This raised the hypothesis that the genes in the
phylogenic branch including MAS1 could have a similarity in
function or signal transduction. We noticed the ability of MAS1 to
promote tumorigenic function in NIH3T3, and in this study,
attemptedtoelucidatethetumorigenicfunctionofMRGD,whichis
reported to work in the central nervous system such as MAS1. We
also investigated the expression of MRGD in human cancer tissues.
We found that MRGD promotes the loss of contact inhibition,
anchorage-independent growth and in vivo tumorigenesis and is also
highly expressed in several human lung cancers, suggesting that
MRGD could play an important role in human cancer.
Results
Effect of MRGD on cell proliferation and tumorigenicity in
vitro
To clarify the effect of MRGD on cell growth, the NIH3T3-
MRGD cell line, which NIH3T3 cells were stably transfected with
MRGD retroviral expression vector was established and its growth-
relatedprofileswereanalyzed.ThegeneexpressionofMRGDinthe
NIH3T3-MRGD cell line was confirmed by RT-PCR and
sequencing (Figure S1). Using the NIH3T3-MRGD cells, the focus
formation assay (see Materials and Methods) was performed, where
significant foci formation was seen in the NIH3T3-MRGD cell
culture, while no suchfoci were seen inNIH3T3-Mock (Figure 1A).
These data indicate that MRGD gene expression cancels contact
inhibitionofNIH3T3cells,oneofthefeaturesofnormalfibroblasts.
To determine MRGD’s other growth-related features, the spheroid
growth assay (see Material and Methods) was performed, where
NIH3T3-MRGD cells and NIH3T3-Mock cells were cultured on a
96-well non-adherent U-bottomed plate, respectively. First, we
noticed that larger spheroids were observed for NIH3T3-MRGD
thanforNIH3T3-Mockonthe5thdayafterplating.Thespheroidof
NIH3T3-Mock shrunk during cultivation, while that of NIH3T3-
MRGD obviously grew day by day, as shown in Figure 1B. We
determined this growth-related character by measuring change in
the diameters of the spheroids and also by measuring difference in
ATPactivityofthespheroids(Figure1CandD).Significantlylarger
spheroid diameters were observed for NIH3T3-MRGD than those
for NIH3T3-Mock from 2 to 8 days after plating (Figure 1C,
p,0.005, Mann-Whitney U test, 2 tails). Also, much more ATP
content was seen for NIH3T3-MRGD compared to that of
NIH3T3-Mock at 6 days after plating (Figure 1D, p,0.005,
Mann-Whitney U test, 2 tails). Similar results were obtained by
[
3H]-Thymidine incorporation assay measurement (Figure S2, File
S1). These results indicate that MRGD significantly promotes
anchorage-independent growth of the normal fibroblast, in other
words, MRGD possess oncogenic capability.
Effect of MRGD on cell proliferation and tumorigenicity in
vivo
Next, to evaluate in vivo tumorigenic activity, we subcutaneously
inoculated NIH3T3-MRGD or NIH3T3-mock to athymic nude
mice.Theremarkablegrowthofgraftedtissuewasobservedwiththe
mice subcutaneously implanted withNIH3T3-MRGD cells but not
with NIH3T3-Mock cells (Table 1). The average tumor volumes of
NIH3T3-MRGD-cells-grafted mice exceeded 2,000 mm
3 in 21
daysafterinoculation.Incontrast,noremarkablegrowthwasseenin
NIH3T3-Mock-cells-grafted mice until 21 days after inoculation. A
clump of cells was found in NIH3T3-Mock-cells-grafted mice 24
daysafterinoculation,however,itwasstillverysmallanditsaverage
volume was less than 400 mm
3. As NIH3T3-MRGD formed the
large clump in vivo, we performed HE staining to confirm that the
NIH3T3-MRGDclumppossessedtumor-likepathologicalfeatures.
HE staining of the grafted tissue sections of NIH3T3-MRGD-cells-
grafted mice showed fibrosarcoma-like morphology (Figure S3).
Taken together, this result suggests that MRGD expression causes
not only in vitro but also in vivo tumorigenicity.
Induction of cell growth by ligand stimulation
To evaluate the effect of beta-alanine, one of the MRGD
ligands [12], on spheroid growth promoted by MRGD, beta-
alanine in various concentrations was added to the spheroid
culture of NIH3T3-MRGD cells or NIH3T3-RASV12 cells.
NIH3T3-Mock cells did not grow well in spheroid culture and no
stable growth was induced even in the presence of beta-alanine
(data not shown), and therefore, the NIH3T3-Mock cell group was
not set in this study. In this experiment, significant promotion of
cell growth by beta-alanine in a dose-dependent manner was
observed for NIH3T3-MRGD as measured by ATP activity
(p,0.05, Mann-Whitney U test, 2-tails), while no effect of beta-
alanine was seen for NIH3T3-RASV12 spheroid growth even with
2000 mg/ml of beta-alanine (Figure 2). These data indicate that
anchorage-independent growth of MRGD expressing cells can be
enhanced by its ligand stimulation.
Expression of MRGD in human cancers
We determined the MRGD expression in several clinical
cancers. First, to clarify the MRGD protein expression level in
lung cancer samples, we performed IHC using a pair of tumor and
normal tissue sections of 33 pairs of human lung cancer samples
(see Materials and Methods). For IHC, the rabbit anti-MRGD
antibody was raised and antigen specificity of the antibody was
confirmed as shown in Materials and Methods; staining signals of
the anti-MRGD antibody at the outer membrane were detected in
formalin-fixed HEK293/avb3 cells transfected with MRGD,
although not in Mock-transfected HEK293/avb3 cells (Figure 3A
and B). With this antibody, 22 out of 33 clinical lung cancer cases
showed MRGD positive signals (22/33): adenocarcinomas (9/10),
poorly-differentiated squamous cell carcinomas (7/10) and well-
differentiated squamous cell carcinomas (6/10) (Table 2). We
noticed especially strong signals in some samples, including
adenocarcinomas (8/9) (Figure 3C and S4), poorly-differentiated
squamous cell carcinomas (3/7) and well-differentiated squamous
cell carcinomas (2/10). On the other hand, no staining signal was
detected for small cell carcinoma (date not shown).
We also analyzed MRGD gene expression in clinical cancers by
quantitative RT-PCR. One hundred and twenty seven sets of
RNA samples with both cancer and non-cancer portions of lung,
esophagus, breast, kidney, stomach, uterus and colon cancer
tissues were used. In the samples of uterus or colon tissue, MRGD
expression in the cancer portion never exceeded 3 times the
amount in the normal portion. As for lung cancers, the average of
MRGD expression in the cancer portion exceeded the amount
equal to 3 times as much as that in the lung normal portion, and
for 12 out of 33 lung pair samples, the MRGD expression in the
cancer portion exceeded 3 times the amount in the paired normal
portion (Figure 4). In all 7 cancer species determined here, the
lung pair samples showed the highest frequency (36%) for higher
MRGD expression in the cancer portion compared to that of the
normal portion with the criteria exceeding 3 times the amount
(Figure 4). Some other cancer samples, such as breasts (3 out of
16), esophagi (2 out of 12), kidneys (1 out of 10) and stomachs (1
out of 25), also showed 3 times higher expression in the cancer
portion compared to that in the normal portion. We did not see a
statistical difference in the overall comparison of the mRNA signal
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38618Figure 1. Tumorigenesis of NIH3T3 cells stably expressing MRGD (NIH3T3-MRGD cells). A. Representative pictures of focus formation in
monolayer cultures of NIH3T3 cells stably expressing Mock (NIH3T3-Mock cells, left) or MRGD (NIH3T3-MRGD cells, right). Cells were stained with
crystal violet after fixing with 4% paraformaldehyde. B. Representative pictures of NIH3T3-MRGD or NIH3T3-Mock spheroid on Days 1 and 7. C.
Spheroid growth curves. The spheroid sizes of NIH3T3-MRGD (closed) or NIH3T3-Mock (open) at Days 2, 3, 5 and 7, are shown with their diameters
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way ANOVA. More precise categorization of the patients must be
necessary to obtain statistical significance. However, the data
clearly indicate that over 3-fold higher expression signals are
shown in the tumor rather than the normal portion in some cancer
patients. Higher expression of the cancer portion in lung cancer
was also very consistent with the results of IHC. These suggest that
the data are very meaningful to indicate the next direction of
research on MRGD expression in cancer.
Discussion
We demonstrated that the MRGD expression induces loss of
contact inhibition, anchorage-independent spheroid growth in vitro
and also tumorigenesis in vivo, which are not seen in the parental
normal fibroblast cells (Figure 1, Table 1). These in functional
phenotypes observed for MRGD are quite similar to those reported
for a representative oncogene, RASV12 [15]. We also confirmed
that RASV12 expression promotes the cancellation of contact
inhibition of normal fibroblast cells and also induces spheroid
growth or anchorage-independent cell growth (data not shown).
Moreover, we showed that NIH3T3-MRGD cells resulted signif-
icant growth of fibrosarcoma-like cells in vivo (Figure S3), and their
morphological phenotypes were quite similar to the NIH3T3-
RASV12 cells (data not shown). These results strongly support that
MRGDtransducestumorigenicsignalingandpromotesanchorage-
independentcellgrowthseenwithRASV12.ItwasreportedthatiPS
cells was made from mouse embryonic fibroblast (MEF) repro-
grammedbyintroducingseveralgenesincludingoncogenes[16].In
this study, we focused on the tumorigenic function of MRGD,
however,itmightbealsoofinteresttoclarifywhetherornotMRGD
is able to promote stemness. The expression of stemness markers
such as Oct-3/4, Nanog and so forth [16–19] in NIH3T3-MRGD
and otherMRGD-positivecells,aswellastheexpressionofMRGD
itself in stem cells and reprogrammed MEFs, are of interest to know
theimportanceofMRGDinthissubjectandshouldbeelucidatedin
the future.
A number of reports indicate that not only oncogene such as
RASV12 but also proto-oncogenes such as ERBB2 and FYN give
similar tumorigenic phenotype in fibroblast cells [20,21]. Addition-
ally, the expression of such oncogenes and/or proto-oncogenes is
often increased in various human cancers and that their cell growth
and anti-apoptotic signals promote not only cancer growth but also
disease progression in cancer patients [2,22–25]. In this report we
found that MRGD mRNA is expressed in clinical human cancer
samples from some patients with lung, breast, esophagus, kidney or
stomach cancer. In addition, we found that some of those cancer
samples expressing MRGD mRNA showed relatively higher
MRGD protein expression compared to the non-cancer portions
from the same patients, although no overall statistical significance
was seen in each tumor type (Figure 4). For lung cancers, our RT-
PCR analyses showed high and frequent MRGD mRNA expres-
sion,andourIHCanalysesrevealedthatthehighestlevel,whichwe
detected for MRGD protein expression, was observed frequently in
human lung cancers (Table 2), especially in lung adenocarcinomas
(Figure 3).Although further analysesofMRGD functionsinhuman
cancercellsandtissuesareneeded,theexpressionprofileofMRGD
inclinicalcancersrevealedinthisstudystronglysuggeststhepossible
contribution of the oncogenic function of MRGD itself and/or a
related signal pathway in some solid tumors such as lung cancers.
GPCRs could be good targets of small molecule inhibitors as well as
antibodies, and therefore MRGD, a GPCR, could serve as a novel
target for cancer therapy. Lung adenocarcinomas might be an
especially interesting cancer type for possible anticancer therapy
targeting MRGD.
Mechanisms by which MRGD promotes oncogenic signals
remain unknown. However, our results indicate that MRGD
expression promotes oncogenic phenotypes in normal cells both in
vitro and in vivo (Figure 1, Table 1), and also that the ligand, beta-
(mean 6 SD). * indicates p,0.005 (Mann-Whitney U test, 2 tails). D. Cell proliferation of spheroid cultures of NIH3T3-MRGD or NIH3T3-Mock.
Luminescence of whole cell ATP contents (means 6 SD) was measured at 6 days after plating. * indicates p,0.005 (Mann-Whitney U test, 2 tails).
doi:10.1371/journal.pone.0038618.g001
Table 1. Tumor volumes of NIH3T3-MRGD or Mock bearing
mice.
Days Tumor Volume (mm
3)
Mock MRGD
3 0.0 0.0 0.0 0.0 0.0 0.0
5 20.1 16.1 58.4 57.8 41.5 130.9
7 70.3 18.5 31.6 161.1 159.2 184.0
10 0.0 10.4 0.0 469.9 314.3 596.4
12 39.3 17.5 0.0 584.0 669.0 859.1
14 58.8 11.8 4.7 1070.6 2166.4 1162.4
17 54.7 11.5 0.0 2548.3 2831.5 1840.6
19 124.2 25.3 110.7 2642.3 3709.0 1974.3
21 124.1 26.0 83.0 2400.4 4409.7 2403.5
24 94.3 380.8 284.2 3722.6 4562.6 2730.5
26 854.2 94.3 495.3 3998.9 5155.4 3292.1
Tumor volumes (mm
3) were calculated according to the following equations:
Tumor volume (mm
3)=1/2 6(tumor length)6(tumor width)
2
doi:10.1371/journal.pone.0038618.t001
Figure 2. MRGD ligand, beta-alanine, promoted cell prolifera-
tion of NIH3T3-MRGD cells. NIH3T3 cells transfected with MRGD or
RASV12 were cultured in RPMI1640 containing 0.1% BSA and various
concentration of beta-alanine for 7 days. Data were obtained from three
independent cell cultures (means 6 SD). * indicates p,0.05 (Mann-
Whitney U test, 2 tails), compared with NIH3T3-MRGD without beta-
alanine, and with NIH3T3-RASV12.
doi:10.1371/journal.pone.0038618.g002
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It was reported that normal levels of beta-alanine was about
3.8 mM in healthy human plasma [26]. Also reported, was that
beta-alanine concentrations in nerve-related tissue are shown to be
about 50 mM in rat sciatic nerve and 60 mM in cat brain [27,28].
Our data indicate that beta-alanine promotes spheroid growth
from 2 mM to 2000 mM in a dose dependent manner, and 50%
growth promotion was observed at 20 mM (Figure 2). Therefore,
beta-alanine in healthy human plasma is high enough to promote
spheroid growth via MRGD. A report has to date, revealed that
high beta-alanine concentration is linked to cancer; in detail,
mammary tumors of rat or mouse contain high level beta-alanine
which have never been found in normal mammary tissue of rat or
mouse [29]. Hence, beta-alanine concentration in plasma or
tumors of cancer patients might be higher than that of normal
subjects. It might be possible that the beta-alanine activates tumor
growth and survival signals in cancer patients through MRGD to
some extent. Additionally, in cancer tissues, high MRGD
expression may cause constitutive transduction of oncogenic
signals, or may cause higher ligand responsiveness than in normal
tissues which leads to promotion of cancer growth. On the other
hand, no report has revealed that beta-alanine promotes cancer
development, and therefore, it is possible that there might be
another MRGD ligand contributing to cancer development
through MRGD. These should be elucidated in the future.
In this study, we demonstrated; 1) tumorigenic activity of
MRGD in vivo and in vitro, 2) MRGD expression in clinical cancer
tissues, 3) promotion of spheroid growth by beta-alanine, the
MRGD ligand, and 4) fibrosarcoma-like morphology of the
grafted tissues of mice subcutaneously implanted MRGD-express-
ing cells. These suggest that MRGD is a potent target in cancer
therapy and that small molecule antagonists, antibodies or RNAi
for MRGD would provide promising anticancer therapy.
Materials and Methods
Written informed consent was received from all participants
when we obtained all clinical tissues, and all the experiments of the
clinical tissues were carried out according to protocols approved
Figure 3. IHC analysis of MRGD expression. Cell block samples were used to confirm the antibody specificity in immunostaining. HEK293/avb3
cells transfected with MRGD expression vector (A) or Mock vector (B) are shown. C. The representative staining of lung adenocarcinoma which is
positive for MRGD.
doi:10.1371/journal.pone.0038618.g003
Table 2. IHC analysis of MRGD expressions in lung cancer.
Histological type Number of cases
Total MRGD positive (%)*







Small cell carcinoma 3 0 (0)
*% was calculated on MRGD positive cases/total cases.
doi:10.1371/journal.pone.0038618.t002
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been conducted according to the relevant national guideline in
2005, when the animal works were studied.
These animal experiment protocols were approved by Sankyo
animal research ethics committee, in Sankyo Co., Ltd., which was
the antecedent of Daiichi Sankyo Co., Ltd.
Materials and cell culture
FBS was purchased from Hyclone (South Logan, UT). DMEM,
RPMI1640, Opti-MEM, Geneticin and Lipofectamine 2000 were
purchased from Life Technologies (Carlsbad, CA). Retrovirus
packaging cell line, 293-10A1, was established in our laboratory
from 293 cell line (ATCC, CRL-1573) by transfecting pCL-10A1
(IMGENEX, Sorrento Valley, CA). The 293-10A1 cell line was
maintained with DMEM medium supplemented with 10% FBS,
3 mg/ml of blasticidin (Wako, Osaka, Japan) under conditions of
5% CO2 at 37uC. NIH3T3 cell line was obtained from ATCC
(CRL-1658) and was adjusted for RPMI1640 medium supple-
mented with 10% FBS. Hexadimethrine bromide was purchased
from Sigma-Aldrich (Tokyo, Japan). HEK293/avb3 cell line was
established from 293 cells (ATCC, CRL-1573) by stable transfec-
tion with integrin av and b3 expression vectors, and was cultured
in DMEM medium supplemented 10% FBS.
Generation of NIH3T3-MRGD cells
cDNA encoding full-length human MRGD, RASV12 or GFP
was cloned into a pLNCX vector (Clontech Laboratories,
Mountain View, CA). For infection, NIH3T3 cells were seeded
in a 10 cm dish and cultured for 1–3 days. The 293-10A1 cells
were plated on a 10 cm collagen I-coated dish (AGC Techno
Glass, Chiba, Japan) and were cultured overnight. pLNCX-
MRGD, pLNCX-RASV12 or pLNCX-Mock was transfected into
the 293-10A1 cells by Lipofectamine 2000. The supernatant of the
transfected 293-10A1 cells were collected, then fresh medium were
added for the next cycle. The collected supernatant was filtrated
with a 0.45 mm PVDF membrane (Millipore, Billerica, MA) and
the equal volume of RPMI1640 medium supplemented with 10%
FBS and 16 mg/ml Hexadimethrine bromide were added. This
viral solution was added to NIH3T3 cells for infection. The series
of these infection procedures were repeated three times every
12 hours. After 12 hours from the last infection, the cells were
cultured with 500 mg/ml of Geneticin for one week to accumulate
cells expressing the target gene.
Focus formation assay
Cells were plated at 1610
5 cells/well on a 6-well cell culture
plate (Corning Japan, Tokyo, Japan) and cultured for one week.
The cultured cells were fixed with 4% paraformaldehyde (Wako,
Osaka, Japan) for 30 minutes at 4uC and were stained with 0.5%
crystal violet (Sigma-Aldrich Japan, Tokyo, Japan).
Spheroid growth assay
NIH3T3-MRGD cells were suspended in RPMI1640 medium
supplementedwith10%FBSor0.1%BSAandplatedon5000cells/
well in 100 ml on a 96-well spheroid plate (Sumitomo Bakelite,
Tokyo,Japan).Inthe casewherebeta-alanine wasadded,cells were
platedon5000cells/wellin80 mlandthen20 mlofbeta-alaninewas
added on the same day. Spheroid growth was measured with any of
the following methods. 1) Measuring spheroid diameter: Spheroid
diameter was measured by ocular micrometer. Each diameter was
calculated from the magnification of an objective lens and an
eyepiece. 2) Measuring spheroid’s ATP quantity: Cell Titer-Glo
LuminescentCellViabilityAssay(PromegaKK,Tokyo,Japan)was
used according to the manufacturer’s instructions. Then, spheroid
with 100 ml of reagent was well pipetted and transferred to a white
flat bottom plate (Corning Japan, Tokyo, Japan). The 1 sec
luminescence of the plate was measured by Mithras LB940
(Berthold Technologies, Wildbad, Germany).
Analysis of in vivo tumorigenicity of MRGD-transfected
NIH3T3 cells
Athymic nude mice (BALB/cAJcl-nu/nu mice, CLEA Japan, 5
weeks old, female) were inoculated subcutaneously with 3610
6
NIH3T3-MRGD cells (n=3) or NIH3T3-Mock cells (n=3), as a
negative control. Tumor volume was measured 3 times per week.
The tumor volumes were calculated according to the following
equations:
Tumor volume mm3 
~1=2| tumor length ðÞ | tumor width ðÞ
2
According to the relevant national guideline, all mice were to be
euthanized if sign of the toxicity such as reduced activity, reduced
appetite,reduceddrinking,licks,guardslimbs,increasedaggression,
Figure 4. Quantitative RT-PCR analysis of MRGD mRNA
expression in clinical samples. One hundred and twenty seven
sets of RNA samples of cancer and non-cancer portions from the same
patients with lung (n=33), esophagus (n=12), breast (n=16), kidney
(n=10), stomach (n=25), uterus (n=12) or colon (n=19) cancer. Ratios
of the amount of MRGD mRNA in tumor portion per that in normal
portion of each case were plotted. The bar indicates the mean of the
ratio in each cancer type.
doi:10.1371/journal.pone.0038618.g004
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anatomy, abnormal posture, fractured appendage and prolapse,
diarrhea, progressive dermatitis, hunched posture, lethargy or
persistent recumbency, coughing, labored breathing, nasal dis-
charge, jaundice and/or anemia, neurological signs, bleeding from
any orifice, self-induced trauma, difficulty with ambulation,
excessive or prolonged hyperthermia or hypothermia, or weight
loss which exceeded 10% of total body weight of negative control
mice, was seen. No sign of toxicity was seen in the mice during this
experiment.
Preparation of rabbit anti-human MRGD polyclonal
antibody
The mixture of 2 kinds of peptides, GTVESALNYSRGSTVH
(16 mer) and ELEGGETPTVGTNEMGA (17 mer), was used as
an antigen. Serums were obtained from rabbits immunized with
the antigen prepared with incomplete Freund’s adjuvant (DIFCO,
Detroit, MI) except for the first immunization, which contained
complete Freund’s adjuvant (DIFCO, Detroit, MI). Finally,
polyclonal IgG antibodies were purified from the serums by an
affinity column with the antigen peptides.
Immunohistochemistry (IHC)
The specificity of anti-MRGD antibodies were validated by
staining HEK293/avb3 cells transfected with MRGD-expressing
or empty vector. These transfectants were fixed with 20% formalin
neutral buffer solution (Wako, Osaka, Japan) and paraffin
embedded to make cell blocks. The cell blocks were cut out to
thin sections by microtome and set on an APS-coated slide glass.
The sections were dried, de-parafinized and pretreated by Biotin
Blocking System (Dako Japan, Tokyo, Japan). The sections were
then blocked with protein block serum-free (Dako Japan, Tokyo,
Japan) and were treated with a polyclonal anti-human MRGD
antibody (1/200) in antibody diluent (Dako Japan, Tokyo, Japan).
The antibody-treated sections were treated with biotinylated anti-
rabbit IgG, then treated with ABC-AP of Vectastain ABC alkaline
phosphatase kit rabbit IgG (CliniScience, Montrouge, France). AP
red of Alkaline Phosphatase Substrate Kit I was used as a coloring
substrate. Cancer tissue sections were prepared from paraffin
embedded blocks and immunohistochemical staining was per-
formed with the ABC method.
Measurement of MRGD gene expression in clinical tissue
Total RNA of tumor or non-tumor clinical tissues from the
same donor were purchased from BioChain (Hayward, CA).
These RNA pair samples were treated with ATP-Dependent
DNase (Toyobo, Osaka, Japan) with 10 units of RNase inhibitor
(Toyobo, Osaka, Japan) for 15 minutes on ice. The DNase was
removed by the total RNA miniprep system (VIOGENE, Taipei
County, Taiwan). To obtain cDNA, a mixture of template total
RNA (2 ng), random primers (9 mer, 50 pmol), ReverTra Ace (10
units, Toyobo, Osaka, Japan) and reaction buffer (50 mM Tris-
HCl pH 7.5, 75 mM KCl, 6 mM MgCl2, 1 mM DTT, 1 mM
dNTP buffer) was incubated at 25uC for 15 minutes, 42uC for
30 minutes, and then 95uC for 3 minutes. Real time-PCR reaction
was performed with TaqMaq One-Step RT-PCR Master Mix
(Life Technologies Japan, Tokyo, Japan) in accordance with
manufacturer’s instructions using the following probe and primers.
MRGD-2 (TaqMan probe sequence): TGTGTGCCAC-
CATGCCTGGCTAATT
MRGD-F2 (Forward primer sequence): GCTCACTA-
CAACCTCAATGTGCC
MRGD-R2 (Reverse primer sequence): GCCACATAGCAA-
GATCTCATCTCTAC
Data were normalized by TaqMan b-actin control reagent (Life
Technologies Japan, Tokyo, Japan). These gene expressions were
measured using Mx3000P QPCR System (Agilent Technology,
Santa Clara, CA).
Statistical Analyses
All the vitro experiments were analyzed by Mann-Whitney U-
tests, except quantitative RT-PCR analysis in clinical samples,
which were analyzed by one-way ANOVA. Reported p values are
two-tails and are considered to be statistically significant at p,0.05.
Supporting Information
Figure S1 Agarose gel electrophoresis of PCR-amplified
cDNA inserts. Nucleic acid sequences of PCR products for
vector inserts were verified. Lane 1 and 3: RT-PCR-amplified
GFP from total RNA of NIH3T3-GFP; lane 2: Amplified GFP
from GFP plasmid (positive control); lane 4 and 6: RT-PCR-
amplified MRGD from total RNA of NIH-3T3-MRGD; lane 5:
Amplified MRGD from MRGD plasmid (positive control).
(TIF)




midine incorporation into the spheroids was measured at 6 days
after plating. * indicates p,0.005 (Mann-Whitney U test, 2 tails).
(TIF)
Figure S3 HE staining of NIH3T3-MRGD grafted tissue
in nude mouse. The NIH3T3-MRGD clumps on 7 days after
inoculation in athymic mice (A, 640, B, 6800) showed a cellular
representative spindle cell tumor tissue type.
(TIF)
Figure S4 HE and IHC stainings of lung adenocarcino-
ma samples with anti-MRGD antibody. HE staining (A, C,
E) and IHC staining (B, D, F) were performed. These are the
examples from three independent patients with lung adenocarci-
noma. Patient 1, A, B; Patient 2, C, D; Patient 3, E, F.
(TIF)
File S1 Material and Methods of Figure S2.
(DOC)
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